

Results of Entitlement Offer

Bluechiip Limited (**Bluechiip** or the **Company**) (**ASX: BCT**) announces the results of its recent Pro-Rata Non-Renounceable Entitlement Offer announced on 5 February 2024 (**Entitlement Offer** or **Offer**).

Highlights:

1. The Entitlement Offer closed on Thursday, 7 March 2024 and raised \$1,302,609.40 before costs from eligible shareholders.
2. The funds raised from the Offer will be used to fund North American sales and marketing activities and for general corporate and working capital purposes.
3. The Company will issue approximately 186,086,939 shares (**New Shares**) under the Offer.
4. The New Shares issued under the Entitlement Offer are expected to be issued on Thursday, 14 March 2024.

The funds raised from this Offer and the earlier February Private Placement total \$2.13 million.

As at the Closing date on Thursday, 7 March 2024 (**Closing Date**) total subscriptions for 186,086,939 New Shares were received from eligible shareholders, raising a total of \$1,302,609.40 (before costs).

The Directors reserve their right to exercise their discretion to issue the Shortfall within 3 months of the Closing Date in accordance with the Corporations Act and ASX Listing Rules.

In accordance with the timetable announced with the ASX on 5 February 2024 trading of the shares to be issued under the Offer is anticipated to commence on Friday, 15 March 2024. An Appendix 2A will be lodged with the ASX on Thursday, 14 March 2024 to apply for quotation of the New Shares issued under the Entitlement Offer.

The Company thanks all shareholders who participated in the Entitlement Offer for their ongoing support to Bluechiip.

END.

Authorised for release by the Bluechiip Limited Board

For more information, please contact:

Corporate enquiries

Andrew McLellan
Managing Director / CEO
Ph: +61 457 823 470
andrew.mclellan@bluechiip.com

Media

Richard Allen
Ph: +61 403 493 049
Oxygen Financial PR
richard@oxygenpr.com.au

About Bluechiip Limited

Bluechiip understands that every biological sample – stem cells, blood, eggs, sperm and other biospecimens – is critical, so our objective is to manage each one with optimal quality in the most efficient way. Bluechiip's Advanced Sample Management Solution is the only one that provides sample temperature with ID in cryogenic environments, driving productivity and improving quality. Bluechiip's solution delivers confidence in every sample.

Bluechiip's unique patented technology is a MEMS-based wireless tracking solution that contains no electronics. It represents a generational change from current tracking methods such as labels (hand-written and pre-printed), barcodes (linear and 2D), and Radio Frequency Identification. Bluechiip tags are either embedded or manufactured into storage products such as vials or bags. Each product is easily identified and critical information, such as sample temperature, detected by readers and stored in the Bluechiip software. In addition to functioning in extreme temperatures, the Bluechiip[®] Advanced Sample management solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.

Bluechiip listed on the ASX in June 2011. Since then, we have significantly developed our technology. Today it has applications in healthcare, including in cryogenic storage facilities (biobanks and biorepositories), pathology, clinical trials and forensics. Other key markets include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.

Bluechiip: Delivering confidence in every sample.

Further information is available at www.bluechiip.com